<DOC>
	<DOCNO>NCT01596387</DOCNO>
	<brief_summary>The purpose study validate integrate pharmacokinetic-pharmacodynamic model administer propofol obese patient . Our hypothesis pharmacokinetic pharmacodynamic change occur increase weight mathematical model administer drug obese patient develop accurately predict dose scheme population .</brief_summary>
	<brief_title>Validation Pharmacokinetic Pharmacodynamic Model Administer Propofol Obese Patients</brief_title>
	<detailed_description>Propofol frequently use IV anesthetic today . Propofol TCI commonly use induction maintenance general anaesthesia obese non obese patient . However , current propofol PK model , use TCI device , derive study include obese patient . A controversial issue propofol dose adjustment population selection adequate size descriptor scale PK parameter , drug administration base total body weight result overdose , conversely , administration base ideal body weight result sub-therapeutic dose . In previous study group , develop PK model capable characterize influence obesity propofol disposition . The purpose study validate model administer propofol obese patient .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<criteria>IMC &gt; 35 kg m2 Scheduled laparoscopic bariatric surgery ASA III patient Between 18 60 yr age . Patients allergy study drug Uncontrolled hypertension Heart block great first degree Take drug act central nervous system within 24 hr surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>anaesthetic iv</keyword>
	<keyword>propofol</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>